Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ9-tetrahydrocannabivarin (THCV), to produce CB 1 receptor inverse agonism symptoms of nausea in rats

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 671-678

  Rock, Erin M ^a   Sticht, Martin A ^a   Duncan, Marnie ^b   Stott, Colin ^b   Parker, Linda A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Porton Down Science Park   (United Kingdom)

Author keywords

anhedonia; cannabidivarin; CB1 receptor antagonism; CB1 receptor inverse agonism; depression; nausea; rimonabant; tetrahydrocannabivarin; THC

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABIDIVARIN; CANNABINOID; CANNABINOID 1 RECEPTOR; DELTA 9 TETRAHYDROCANNABIVARIN; DRONABINOL; LITHIUM CHLORIDE; RIMONABANT; SACCHARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONDITIONED GAPING; CONTROLLED STUDY; DRUG EFFECT; INVERSE AGONISM; MALE; NAUSEA; NONHUMAN; PALATABILITY; PRIORITY JOURNAL; RAT;

ANHEDONIA; CANNABIDIVARIN; CB1 RECEPTOR ANTAGONISM; CB1 RECEPTOR INVERSE AGONISM; DEPRESSION; NAUSEA; RIMONABANT; TETRAHYDROCANNABIVARIN; THC;

ANIMALS; BEHAVIOR, ANIMAL; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DRONABINOL; DRUG PARTIAL AGONISM; LITHIUM CHLORIDE; MALE; NAUSEA; PHYTOCHEMICALS; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1;

EID: 84884554661     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12322     Document Type: Article

References (53)

1. Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, et al. (2010). Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 39: 148-155.
2. Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V, et al. (2010). The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160: 677-687.
3. Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, et al. (2013). Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168: 1456-1470.
4. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. (2007). A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293: R2185-R2193.
5. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. (1979). Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91: 819-824.
6. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, et al. (2010). A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161: 629-642.
7. Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA, (2007). Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl) 190: 135-143.
8. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
9. De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, et al. (2012). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 204: 255-266.
10. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 219: 859-873.
11. Despres JP, (2009). Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des 15: 553-570.
12. Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, et al. (1979). Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91: 825-830.
13. 9-THCV in animal models of Parkinson's disease. Br J Pharmacol 163: 1495-1506.
14. 9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51: 1522-1532.
15. Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, et al. (2012). Cannabidivarin is anticonvulsant in mouse and rat in vitro and in seizure models. Br J Pharmacol 167: 1629-1642.
16. Hillig KW, Mahlberg PG, (2004). A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot 91: 966-975.
17. Jarrett MM, Limebeer CL, Parker LA, (2005). Effect of Delta9-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test. Physiol Behav 86: 475-479.
18. Jarrett MM, Scantlebury J, Parker LA, (2007). Effect of delta9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiol Behav 90: 425-430.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Limebeer CL, Parker LA, (1999). Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport 10: 3769-3772.
21. Limebeer CL, Parker LA, (2000). The antiemetic drug ondansetron interferes with lithium-induced conditioned rejection reactions, but not lithium-induced taste avoidance in rats. J Exp Psychol Anim Behav Process 26: 371-384.
22. Limebeer CL, Parker LA, (2003). The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacology (Berl) 166: 120-126.
23. Limebeer CL, Litt DE, Parker LA, (2009). Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats. Psychopharmacology (Berl) 203: 763-770.
24. Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, et al. (2010). Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 161: 336-349.
25. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD, (2005). The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) 180: 286-293.
27. de Mattos Viana B, Prais HA, Daker MV, (2009). Melancholic features related to rimonabant. Gen Hosp Psychiatry 31: 583-585.
28. Mechoulam R, Parker LA, Gallily R, (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S-19S.
29. Merkus FW, (1971). Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature 232: 579-580.
30. O'Brien LD, Wills KL, Segsworth B, Dashney B, Rock EM, Limebeer CL, et al. (2013). Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 103: 597-602.
31. Orr LE, McKernan JF, Bloome B, (1980). Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140: 1431-1433.
32. Parker LA, Limebeer CL, (2008). Cannabinoids in the management of nausea and vomiting. In:, Köfalvi A, (ed.). Cannabinoids and the Brain. Springer: New York, pp. 259-273.
33. Parker LA, Mechoulam R, (2003). Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci 38: 133-145.
34. Parker LA, Mechoulam R, Schlievert C, (2002). Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13: 567-570.
35. Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P, (2003). Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) 166: 156-162.
36. Parker LA, Rana SA, Limebeer CL, (2008). Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62: 198-209.
37. Parker LA, Limebeer CL, Rana SA, (2009). Conditioned disgust, but not conditioned taste avoidance, may reflect conditioned nausea in rats. In:, Reilly, S, and, Schachtman, TR, (eds). Conditioned Taste Aversions: Behavioral and Neural Processes. Oxford University Press: New York.
38. Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH, et al. (2007). The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150: 586-594.
39. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L, (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156: 1154-1166.
40. Rock E, Bolognini D, Limebeer C, Cascio M, Anavi-Goffer S, Fletcher P, et al. (2012). Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165: 2620-2634.
41. Rock EM, Parker LA, (2013). Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol 169: 685-692.
42. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA, (2008). The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) 196: 389-395.
43. Rock EM, Benzaquen J, Limebeer CL, Parker LA, (2009). Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor. Pharmacol Biochem Behav 91: 537-541.
44. Sallan SE, Zinberg NE, Frei E, 3rd, (1975). Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293: 795-797.
45. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, et al. (2007). Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25: 2773-2785.
46. Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, et al. (2008). The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33: 946-955.
47. Sink KS, Vemuri VK, Wood J, Makriyannis A, Salamone JD, (2009). Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 91: 303-306.
48. Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, et al. (2010). Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20: 112-122.
49. Sweet DL, Miller NJ, Weddington W, Senay E, Sushelsky L, (1981). delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 21: 70S-75S.
50. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. (2010). Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120: 2953-2966.
51. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, et al. (2005). Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917-926.
52. Tubaro A, Giangaspero A, Sosa S, Negri R, Grassi G, Casano S, et al. (2010). Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins. Fitoterapia 81: 816-819.
53. Tuerke KJ, Leri F, Parker LA, (2009). Antidepressant-like effects of paroxetine are produced by lower doses than those which produce nausea. Pharmacol Biochem Behav 93: 190-195.